Document is current

Article History

Received: 9 September 2020

Accepted: 25 November 2020

First Online: 4 January 2021

Change Date: 15 January 2021

Change Type: Update

Change Details: A space was added in the 4th author's last name in the original article. The article has been updated to rectify the error.

Ethics approval and consent to participate

: Ethics Committee approval from each country of the HCP that answered the survey was deemed unnecessary according to the International Ethical Guidelines for Health-related Research Involving Humans (CIOMS, Geneva 2016), since no data from any patient was collected. Results analysed in this manuscript come from a survey among European GPs intended to gather their opinion on chronic migraine management. The survey was performed following the European General Data Protection Regulation. All survey participants gave their written consent to analyse their answers anonymously. The anonymity of the participants was secured as all answers were aggregated before their analysis.

: Not applicable.

: Dr. Ryvlin reports personal fees from Novartis, during the conduct of the study and personal fees from Eli Lilly and Novartis outside the submitted work.Dr. Skorobogatykh reports personal fees from Novartis during the conduct of the study; and personal fees from Novartis and Teva, outside the submitted work.Dr. Negro reports personal fees from Novartis during the conduct of the study, and personal fees from Allergan, Eli Lilly and Teva, outside the submitted work.Dr. Sanchez-De La Rosa reports he is an employee and stakeholder of Novartis Pharma AG.Dr. Israel-Willner has nothing to disclose.Dr. Sundal reports personal fees from Novartis, during the conduct of the study and personal fees from Allergan, outside the submitted work.Dr. MacGregor reports personal fees from Novartis, during the conduct of the study; personal fees from Eli Lilly, outside the submitted work; and Co-author of Aids to management of headache disorders in primary care (2nd edition): On behalf of the European Headache Federation and Lifting the Burden: The Global Campaign against Headache. Vol. 20, Journal of Headache and Pain. The Journal of Headache and Pain; 2019.Dr. Guerrero reports personal fees from Novartis during the conduct of the study, and personal fees from Allergan, Exeltis, Eli Lilly and Teva outside the submitted work.